A Phase II Open Label, Single-Blind, Multicenter, Single-Dose, Dose-Escalating Safety and Tolerability Study of Intrathecal Xen2174 in Oncology Patients

Trial Profile

A Phase II Open Label, Single-Blind, Multicenter, Single-Dose, Dose-Escalating Safety and Tolerability Study of Intrathecal Xen2174 in Oncology Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2008

At a glance

  • Drugs XEN 2174 (Primary)
  • Indications Cancer pain; Various toxicities
  • Focus Adverse reactions
  • Sponsors Xenome
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top